{"id":8682,"date":"2020-03-17T15:53:20","date_gmt":"2020-03-17T10:23:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8682"},"modified":"2021-07-24T12:57:50","modified_gmt":"2021-07-24T07:27:50","slug":"recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly","title":{"rendered":"Moderna\u2019s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Moderna announces dozing of first patient with its mRNA1273 vaccine<\/strong><\/h2>\n\n\n\n<p>The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\/\">COVID-19<\/a>. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clinical trial has been supported by Coalition for Epidemic Preparedness Innovations (CEPI).<\/p>\n\n\n\n<p>The company has announced that the first patient has been dozed with the vaccine to protect against <a href=\"https:\/\/www.delveinsight.com\/blog\/questions-and-answers-on-coronavirus-covid-19\/\">COVID-19<\/a> due to SARS-CoV-2 virus. The Phase I study is being conducted by the National Institutes of Health (NIH) under its own Investigational New Drug (IND) application and plans to for the Phase II trials. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>AcelRx Pharmaceuticals is purchasing TetraPhase Pharmaceuticals for USD 14.4 Million<\/strong><\/h2>\n\n\n\n<p>Headquartered in Redwood City, California, AcelRx, is acquiring Tetraphase at an exchange ratio of 0.6303 shares of AcelRx, for each share of Tetraphase. Moreover, the deal also involves a contingent value right (CVR) based on Xerava (eravacycline for injection) hitting a specific net sales figure beginning in 2021.<\/p>\n\n\n\n<p>The companies are bound with a co-promotion agreement for the commercialization of <strong>Xerava<\/strong> for complicated intra-abdominal infections (cIAI) and <strong>Dsuvia<\/strong> for acute pain in medically supervised settings.  <\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The US FDA grants Breakthrough designation to baricitinib<\/strong><\/h2>\n\n\n\n<p>The U.S. Food and Drug Administration (FDA) has granted Eli Lilly\u2019s baricitinib Breakthrough Therapy designation for treating <a href=\"https:\/\/www.delveinsight.com\/report-store\/alopecia-areata-market\">alopecia areata <\/a>(AA).<\/p>\n\n\n\n<p>&nbsp;AA &#8211; an autoimmune disease \u2013 results in hair loss on the scalp, face and other areas of the body. Once-daily oral JAK inhibitor- <strong>Baricitinib<\/strong>, sold under the brand name \u2013 Olumiant, is approved for treating severely active <a href=\"https:\/\/www.delveinsight.com\/report-store\/juvenile-rheumatoid-arthritis-market\">rheumatoid arthritis<\/a> in adults who have one or more TNF \u2013 tumor necrosis factor.  <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Moderna announces dozing of first patient with its mRNA1273 vaccine The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clinical trial has been supported by Coalition [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8683,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18137,16873,18139,228,349,16972,639,5789,2019,18138],"industry":[17225],"therapeutic_areas":[17227],"class_list":["post-8682","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acelrx-pharmaceuticals","tag-alopecia-areata","tag-baricitinib","tag-eli-lilly","tag-latest-pharma-news","tag-moderna","tag-pharma-news","tag-recent-pharma-news","tag-rheumatoid-arthritis","tag-tetraphase-pharmaceuticals","industry-pharmaceutical","therapeutic_areas-immunological-and-autoimmune-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Moderna\u2019s mRNA1273; AcelRx to acquire TetraPhase; Eli Lilly\u2019s baricitinib<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) has granted Eli Lilly\u2019s baricitinib Breakthrough Therapy designation for treating alopecia areata (AA)..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna\u2019s mRNA1273; AcelRx to acquire TetraPhase; Eli Lilly\u2019s baricitinib\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) has granted Eli Lilly\u2019s baricitinib Breakthrough Therapy designation for treating alopecia areata (AA)..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-17T10:23:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/17152841\/Pharma-news_17.03.2020.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Moderna\u2019s mRNA1273; AcelRx to acquire TetraPhase; Eli Lilly\u2019s baricitinib","description":"The U.S. Food and Drug Administration (FDA) has granted Eli Lilly\u2019s baricitinib Breakthrough Therapy designation for treating alopecia areata (AA)..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly","og_locale":"en_US","og_type":"article","og_title":"Moderna\u2019s mRNA1273; AcelRx to acquire TetraPhase; Eli Lilly\u2019s baricitinib","og_description":"The U.S. Food and Drug Administration (FDA) has granted Eli Lilly\u2019s baricitinib Breakthrough Therapy designation for treating alopecia areata (AA)..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-03-17T10:23:20+00:00","article_modified_time":"2021-07-24T07:27:50+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/17152841\/Pharma-news_17.03.2020.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly","name":"Moderna\u2019s mRNA1273; AcelRx to acquire TetraPhase; Eli Lilly\u2019s baricitinib","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/17152841\/Pharma-news_17.03.2020.jpg","datePublished":"2020-03-17T10:23:20+00:00","dateModified":"2021-07-24T07:27:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The U.S. Food and Drug Administration (FDA) has granted Eli Lilly\u2019s baricitinib Breakthrough Therapy designation for treating alopecia areata (AA)..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-moderna-acelrx-tetraphase-eli-lilly#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/17152841\/Pharma-news_17.03.2020.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/17152841\/Pharma-news_17.03.2020.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/17152841\/Pharma-news_17.03.2020-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AcelRx Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">alopecia areata<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Baricitinib<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Moderna<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rheumatoid arthritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">TetraPhase Pharmaceuticals<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AcelRx Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">alopecia areata<\/span>","<span class=\"advgb-post-tax-term\">Baricitinib<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Moderna<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">rheumatoid arthritis<\/span>","<span class=\"advgb-post-tax-term\">TetraPhase Pharmaceuticals<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 17, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 17, 2020 3:53 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8682","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8682"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8682\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8683"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8682"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8682"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8682"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8682"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8682"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}